Sanofi-Aventis Deal Means More Leverage With Managed Care
Executive Summary
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call
You may also be interested in...
Acomplia Pricing Likely To Follow Statin Model, Sanofi Says
Sanofi is likely to price the weight loss/smoking cessation agent Acomplia on par with the daily cost of statin therapy, the company suggested during an Aug. 31 analyst call
Sanofi-Aventis Begins Operations; Markham, Senior Aventis Execs Depart
Sanofi-Aventis is beginning operations as a top 10 pharmaceutical company in the U.S
Acomplia Pricing Likely To Follow Statin Model, Sanofi Says
Sanofi is likely to price the weight loss/smoking cessation agent Acomplia on par with the daily cost of statin therapy, the company suggested during an Aug. 31 analyst call